Lucas Montarce

We release our guide for 2026.

25% is the midpoint of the growth that we expect to see in 2026.

It's industry-leading growth, and that's a continuation of the momentum that we see as well in 2025.

By the way, thinking about the Q4 that we also release the revenue that we deliver in the fourth quarter, we deliver 43% growth.

So it's a continuation of that strong momentum getting into 2026.

What is driving that is the similar drivers, the key growth products that we have.

Of course, the incretin is getting all the attention, but we have a breadth of a portfolio across all our therapeutic areas that will continue to drive that growth into 2026.

Thinking about the drivers that you mentioned, we talk about the incrementing portfolio both in the U.S.

and OUS.

You see that the market in the fourth quarter on the anti-obesity space grew 85%, and we actually outpaced that growth in the fourth quarter, and very strong growth as well in type 2 diabetes, 17%.

So we continue to drive that growth into 2026.

You mentioned as well the introduction of Orfolgripon.

Very excited.

We submitted for regulatory approval in the fourth quarter, and we expect to have regulatory action as early as Q2.

So expect to see as well our oral bill coming into the market, a very exciting opportunity to expand the market.

In addition to that, we are expanding through access as well with the agreement that we have signed with the administration in Medicare that we expect not later than July will be

provide access to Medicare patients, more than 40 million patients that could benefit to have access to anti-obesity medications as well.

So very exciting time, very exciting opportunity ahead of us.

Yeah, it's early days at this time.

We just put the guide out there.